Navigation Links
China Medicine Enhances Management Team with Appointments of New Chief Financial Officer and Finance Manager
Date:8/31/2009

GUANGZHOU, China, Aug. 31 /PRNewswire-Asia/ -- China Medicine Corporation (OTC Bulletin Board: CHME) ("China Medicine" or "the Company"), a developer and leading distributor of prescription and over the counter pharmaceuticals, traditional Chinese medicines (TCM), nutritional and dietary supplements, and medical devices and medical formulations, today announced the appointment of Richard P. Wu as its new Chief Financial Officer, effective August 25, 2009. Mr. Wu replaces Ms. Huizhen Yu, who had served as Chief Financial Officer of China Medicine since February 2006. Ms. Yu now serves as Controller of the Company and its subsidiaries, including our wholly-owned operating subsidiary, Guangzhou Konzern Medicine Co., Ltd. In addition, the Company also appointed Mr. Robert Lu to a newly created position of Finance Manager, which involves cash planning, internal and external reporting, tax planning and capital budgeting.

Richard P. Wu has over 14 years of experience in accounting and finance both in China and the U.S. including financial reporting, disclosure and regulatory compliance, financial planning, taxation, and debt and equity financing. Mr. Wu also has a strong legal background as a practicing lawyer in China from 1987 to 1992. Prior to joining China Medicine, Mr. Wu was Chief Financial Officer and Executive Vice President of China Natural Gas, Inc., a NASDAQ Global-listed company, from 2008 to 2009. From January 2004 to May 2007 he was Chief Financial Officer and Corporate Senior Vice President of The AlliancePharm U.S. LLC's China operations, where he had full finance and accounting responsibility for the sourcing and contract manufacturing business for active pharmaceutical ingredients and managed a finance and accounting team of over 100 people. From December 1999 to December 2003 he was Chief Financial Officer and Corporate EVP of MeetChina.com Inc.'s China business, an online cross-border ecommerce portal in China. From October 1997 to December 1999, he was senior director of Finance and VP Investment of the Paging Products Group in Greater China of Motorola Inc., a New York Stock Exchange-listed company. He also served as Investment Banking Associate and Vice President of Lehman Brothers Inc.'s New York and Hong Kong offices from 1995 to 1997. Mr. Wu graduated from the Wharton School, University of Pennsylvania in 1995 with an MBA degree in finance and accounting. He received a Master of Justice Administration degree from Indiana University in 1993, and a Master of Law degree from China University of Political Science and Law in 1987. Mr. Wu obtained a Bachelor of Arts degree from Zhengzhou University, China, in 1985 and is fluent in English and Mandarin.

Robert Lu has over six years of experience in finance and accounting and most recently served as international and regional tax manager for Huawei Technologies Co., Ltd, a global telecommunications provider based in Shenzhen, China. He holds a bachelor's degree in accounting from the Harbin Institute of Technology and is fluent in both English and Mandarin.

"We are very happy to strengthen our financial management team with the appointment of Mr. Wu as Chief Financial Officer and Mr. Lu as Finance Manager," stated Mr. Senshan Yang, Chairman and CEO of China Medicine Corporation. "Given Mr. Wu's track record of success and extensive corporate accounting and financial experience, we believe he will make a significant contribution to our executive team as China Medicine continues to evolve as a public company. Mr. Wu will also allow us to better support our relationship with the investment community as we seek to list our shares on a senior stock exchange." Mr. Yang added, "We would also like to thank Ms. Yu for her continued dedication as she will now serve as Controller of China Medicine and our subsidiaries."

About China Medicine Corporation

China Medicine Corporation is a developer and leading distributor of prescription and over the counter ("OTC") drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. The Company also has its research and development force for certain products it manufactures through OEM arrangement and distributes. The Company distributes its products to wholesale distributors including more than 300 hospitals and 500 medicine companies that sell to over 2,000 drug stores in 28 provinces throughout China. The Company actively develops a number of proprietary products for a variety of uses, including oncology, high blood pressure and the removal of toxins from food and animal feeds. For more information visit the Company's website at http://www.chinamedicinecorp.com .

Cautionary Statement

This press release contains forward-looking statements concerning the Company's business and products. The Company's actual results may differ materially depending on a number of risk factors including, but not limited to, the following: general economic and business conditions, obtaining regulatory approval for new products, the expected contribution of higher margin products, government support for rural health care, competition from existing and new competitors, changes in technology, and various other factors beyond its control. All forward-looking statements are expressly qualified in their entirety by this Cautionary Statement and the risk factors detailed in the Company's reports filed with the Securities and Exchange Commission. China Medicine Corporation undertakes no duty to revise or update any forward-looking statement to reflect events or circumstances after the date of this release.

    For more information, please contact:

    Company Contact:
    China Medicine Corp.
     Mr. Richard P. Wu
     Chief Financial Officer
     Tel:   +86-20-8739-1718
     Email: konzern08@163.com

    Investor Relations Contact:
    CCG Investor Relations
     Mr. Crocker Coulson, President
     Tel:     +1-646-213-1915 (NY Office)
     Email:   crocker.coulson@ccgir.com
     Website:http://www.ccgirasia.com

'/>"/>
SOURCE China Medicine Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. China Sky One Medical, Inc. to Hold Annual Meeting of Shareholders on September 24, 2009
2. Linkwell Corporation Announces Launch of the Establishment of 100 Model Hospitals Across China
3. Linkwell Corporation Announces Launch of the Series of Handwashing Contest Across China
4. China Healthcare Corp. Provides Update on JV to Build its First Hospital in China
5. China Kangtai Cactus Biotech to Attend Rodman & Renshaw Conference and Meet with Investors in September
6. China Nepstar Chain Drugstore Announces Special Dividend
7. China Nepstar Chain Drugstore Reports Second Quarter 2009 Financial Results
8. China Nepstar Chain Drugstore Announces Management Change
9. China Shenghuo Reports Unaudited Financial Results for the Second Quarter of 2009
10. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter Fiscal 2010 Financial Results
11. CordLife Makes Headway into China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2017)... San Mateo, CA (PRWEB) , ... February 26, 2017 , ... ... Bay Area cities as diverse as Millbrae, Belmont, and Palo Alto, is proud to ... San Mateo. Many Bay Area consumers look for home care close to home, and ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... in staffing, scheduling, and reporting for healthcare organizations. This comprehensive and customizable ... entire staffing process. StaffBridge technology improves staffing efficiency, maximizes resource allocation, collects ...
(Date:2/26/2017)... Florida (PRWEB) , ... February 26, 2017 , ... ... of Parkinson’s disease (PD) in persons with a specific LRRK2 mutation, according to ... Congress. , Previous studies have provided evidence of a link between pesticides and ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... on tooth replacement options at his office, Antoine Dental Center. Currently, patients can ... $18,499. Some restrictions may apply, but patients can learn more about these offers ...
(Date:2/24/2017)... ... February 24, 2017 , ... An in-depth computational analysis of genetic variants ... points to eight genes that may explain why susceptibility to one of the disorders ... a study published today in the journal npj Schizophrenia. , “There is a ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Research and Markets has announced the addition ... Industry Forecast to 2025" report to their offering. ... The Global Wireless Health ... over the next decade to reach approximately $330.5 billion by 2025. ... for all the given segments on global as well as regional ...
(Date:2/24/2017)... 2017 Research and Markets has announced the addition ... report to their offering. ... The latest research Dry eye Drugs Price Analysis and Strategies - ... market. The research answers the following questions: ... clinical attributes? How are they positioned in the Global Dry eye market? ...
(Date:2/24/2017)... Juan Monteverde , founder and managing ... boutique securities firm headquartered at the Empire State Building ... that a class action lawsuit has been filed in the ... Inotek Pharmaceuticals Corporation (NASDAQ:  ITEK)("Inotek" or the "Company") on ... 2015 and December 30, 2016, inclusive (the "Class Period").  ...
Breaking Medicine Technology: